fashion -WSS

fashion

author：fashion 2025-09-06 01:59:11 - browse：63327

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Why Novartis is going to walk from its acquisition of MorphoSys

hotspot

WSS

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Unique patient identifier: Experts argue the benefits, pitfalls

Readout LOUD: Venture capital, Gilead, and more M&A

CDC marks new Covid

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

explore

fashion

Wikipedia

George Santos makes 1st court appearance after pleading not guilty to 13 counts

With psoriasis trial ahead, Alumis raises $259 million

Medicare proposal to cover medical devices draws a mixed reaction

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Jerome Adams on the need for new antivirals for Covid

In his State of the Union, Biden takes clear aim at 'Big Pharma'

The high cost of giving birth even with insurance

AstraZeneca stays mum on Medicare drug pricing negotiations

New air purifier tech could be key to improving indoor air quality

AstraZeneca stays mum on Medicare drug pricing negotiations

entertainment

AI gets buy

Bernie brings in new pharma CEOs to talk drug prices

Sen. Paul opposes bill to ban Chinese biotechs

Global cancer cases to surge 77% by 2050, WHO report says

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

With psoriasis trial ahead, Alumis raises $259 million

hotspot

hotspot

focus

entertainment